共 121 条
[1]
Strosberg J(2017)Phase 3 trial of (177)Lu-dotatate for midgut neuroendocrine tumors N Engl J Med 376 125-135
[2]
El-Haddad G(2017)Long-term efficacy, survival, and safety of [(177)Lu-DOTA(0), Tyr(3)]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors Clin Cancer Res 23 4617-4624
[3]
Wolin E(2020)The efficacy of (177)Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in patients with metastatic neuroendocrine tumours: a systematic review and meta-analysis J Cancer Res Clin Oncol 146 1533-1543
[4]
Hendifar A(2018)Correlation of dose with toxicity and tumour response to (90)Y- and (177)Lu-PRRT provides the basis for optimization through individualized treatment planning Eur J Nucl Med Mol Imaging 45 2426-2441
[5]
Yao J(2016)Radiolabeled somatostatin analogue therapy of gastroenteropancreatic cancer Semin Nucl Med 46 225-238
[6]
Chasen B(2013)Individualized dosimetry of kidney and bone marrow in patients undergoing 177Lu-DOTA-octreotate treatment J Nucl Med 54 33-41
[7]
Brabander T(2022)Phase II trial demonstrates the efficacy and safety of individualized, dosimetry-based (177)Lu-DOTATATE treatment of NET patients Eur J Nucl Med Mol Imaging 49 3830-3840
[8]
van der Zwan WA(2019)Personalized (177)Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial Eur J Nucl Med Mol Imaging 46 728-742
[9]
Teunissen JJM(2019)(177)Lu-DOTATATE for the treatment of gastroenteropancreatic neuroendocrine tumors Expert Rev Gastroenterol Hepatol 13 1023-1031
[10]
Kam BLR(2010)177Lu-[DOTA0, Tyr3] octreotate therapy in patients with disseminated neuroendocrine tumors: Analysis of dosimetry with impact on future therapeutic strategy Cancer 116 1084-1092